Pralatrexate Completed Phase 2 Trials for Neoplasms, Bladder / Cancer, Bladder / Transitional Cell Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00722553Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder